CAJ | 학술논문

目的探讨培美曲塞联合顺铂二线治疗治疗晚期卵巢癌的疗效以及不良反应.方法经病理学或细胞学确诊的晚期卵巢癌患者41例,中位年龄48岁,KPS评分≥60.培美曲塞500mg/m2第1d+顺铂25mg/m2第1-3d,每3周为1个周期.至少2周期以上可评价疗效及不良反应.结果41例中38例可评价疗效,无CR病例(0%),PR17例(44.74%),SD15例(39.47%),PD6例(15.79%),总有效率(CR+PR)为44.74%,临床获益率(CR+PR+SD)为84.21%.38例可评价疗效者,中位无进展生存期5.3个月,中位生存期13.2个月,1年生存率34.21%(13/38).主要不良反应为粒细胞下降、贫血和胃肠道反应.结论培美曲塞联合铂类治疗晚期卵巢癌疗效确切,不良反应发生率低,耐受性较好.
목적탐토배미곡새연합순박이선치료치료만기란소암적료효이급불량반응.방법경병이학혹세포학학진적만기란소암환자41례,중위년령48세,KPS평분≥60.배미곡새500mg/m2제1d+순박25mg/m2제1-3d,매3주위1개주기.지소2주기이상가평개료효급불량반응.결과41례중38례가평개료효,무CR병례(0%),PR17례(44.74%),SD15례(39.47%),PD6례(15.79%),총유효솔(CR+PR)위44.74%,림상획익솔(CR+PR+SD)위84.21%.38례가평개료효자,중위무진전생존기5.3개월,중위생존기13.2개월,1년생존솔34.21%(13/38).주요불량반응위립세포하강、빈혈화위장도반응.결론배미곡새연합박류치료만기란소암료효학절,불량반응발생솔저,내수성교호.
Objective To evaluate the efficacy and side effects for chemotherapy with pemetrexed combined with cisplatin in the treatment of advanced ovarian cancer. Methods The study was conducted on 41 patients with advanced ovarian cancer who had failed to previous chemotherapy and all these patients had been confirmed with pathology or cytology. Among the 41 cases, the median age was 48 years old, KPS scale was 60-100,received pemetrexed 500mg/m2 d1 and cisplatin 25mg/m2 d1-3 intravenous infusion, with 21 days as one cycle. All patients who received 2 or more cycles could be evaluated. Results There was no case with complete response, 17 cases got partial response, 15 got stable disease and 6 cases got progression disease. So the overall response rate was 44.74%. The clinical benefit rate was 84.21%. The median time to diease progression was 5.3 months and the median survival time was 13.2 months. The 1-year survival rate was 34.21%. The common adverse effects were leucopenia, anemia and gastrointestinal response. Conclusions Chemotherapy with pemetrexed combined with cisplatin is effective and feasible for advanced ovarian cancer. So pemetrexed is one of the choices for advanced ovarian cancer patients who need two or more line therapy.